TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ).
Venus Medtech (Hangzhou) Inc. has announced the proposed re-election and appointment of directors and supervisors for the third session of its Board and Supervisory Committee. The company plans to re-elect and appoint a total of eight directors and three supervisors, with the re-election proposal set to be approved at the 2024 annual general meeting. This strategic move is expected to ensure continuity in leadership and governance, potentially impacting the company’s operational stability and stakeholder confidence.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a company based in China, operating in the medical technology industry. It focuses on the development and commercialization of innovative medical devices, particularly in the cardiovascular sector.
Average Trading Volume: 9,465,020
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.12B
See more insights into 2500 stock on TipRanks’ Stock Analysis page.